СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ РЕСТЕНОЗА КОРОНАРНЫХ АРТЕРИЙ ПОСЛЕ ЭНДОВАСКУЛЯРНОГО СТЕНТИРОВАНИЯ: ОБЗОР ЛИТЕРАТУРЫ
Введение. Сегодня лидирующую позицию среди инвазивных методик лечения ишемической болезни сердца (ИБС) занимают чрескожные коронарные вмешательства (ЧКВ). Несмотря на постоянное развитие технологии ЧКВ частота развития рестеноза в зоне стентирования коронарной артерии остается на достаточно высоком уровне и составляет порядка 15-57%. При этом субстратом окклюзии, как правило, служит не атеросклероз, а фиброз, что вызывает сложность повторной реканализации и более низкий процент технического успеха в восстановлении кровотока. Своевременная диагностика с целью раннего выявления рестеноза и его коррекции представляется чрезвычайно актуальной проблемой для практического здравоохранения, что обуславливает научный и практический интерес к данному вопросу и служит основанием для проведения настоящего исследования.
Цель: изучить современное состояние проблемы рестеноза коронарных артерий после эндоваскулярного стентирования по данным литературы.
Стратегия поиска. проведен поиск и анализ научных публикаций в базах данных и web-ресурсах MEDLINE, Google Scholar, Cyberleninka, Springer Link и электронной библиотеке eLIBRARY. Период поиска с 2012 по 2020 годы. Критерии включения: отчеты о рандомизированных и когортных исследованиях, систематические обзоры и метаанализы, протоколы диагностики и лечения, статьи на английском и русском языках. Критерии исключения: личные сообщения, газетные публикации, тезисы, статьи с нечеткими выводами, а также статьи с платным доступом. Всего было проанализировано 153 публикации, из них 66 включены в данный обзор.
Результаты. На сегодняшний день опубликовано множество научных работ, направленных на изучение проблемы рестеноза коронарных артерий. Однако, в целом, проблема рестеноза коронарных артерий остается нерешенной, большинство работ в этом направлении посвящено вопросу выбора метода реваскуляризации, отсутствует четкая «иерархия» факторов риска развития рестеноза после эндоваскулярного стентирования.
Выводы. Дальнейшие научные разработки в этом направлении будут иметь особую актуальность и позволят не только выполнить оценку степени влияния отдельных факторов риска и их комбинаций на развитие рестеноза коронарных артерий, но и разработать рекомендации по отбору пациентов с высоким риском рестеноза для своевременного определения показаний к повторной коронарографии и реваскуляризации.
Наталья С. Землянская1, https://orcid.org/0000-0003-1968-3246
Гульмира А. Дербисалина1, https://orcid.org/0000-0003-3704-5061
Марат А. Арипов2,
Виктор В. Землянский3, https://orcid.org/0000-0002-2458-8086
1 НАО «Медицинский университет Астана», Кафедра общей врачебной практики с курсом доказательной медицины, г. Нур-Султан, Республика Казахстан;
2 АО «Национальный научный кардиохирургический центр», г. Нур-Султан, Республика Казахстан;
3 Медицинский центр «iClinic», г. Нур-Султан, Республика Казахстан.
1. Алимов Д.А., Жалалов Б.З., Ганиев У.Ш. Рестеноз стента с точки зрения эндотелиальной дисфункции // Вестник экстренной медицины. 2017. №3. С. 109-112. URL: https://cyberleninka.ru/article/n/restenoz-stenta-s-tochki-zreniya-endotelialnoy-disfunktsii (дата обращения: 28.05.2020).
2. Березовская Г.А., Ганюков В.И., Карпенко М.А. Рестеноз и тромбоз внутри стента: патогенетические механизмы развития и прогностические маркеры // Российский кардиологический журнал. 2012. №6. С. 91-95. URL: https://doi.org/10.15829/1560-4071-2012-6-91-95 (дата обращения: 05.02.2020).
3. Веселовская Н.Г., Чумакова Г.А., Суворова А.А., Гриценко О.В., Субботин Е.А. Гендерные различия факторов риска рестеноза коронарных артерий после их стентирования у пациентов с ожирением // Современные проблемы науки и образования. 2012. №5. С. 64-69. URL: https://www.science-education.ru/ru/article/view?id=7218 (дата обращения: 03.02.2020).
4. Винтизенко С.И., Огородова Л.М., Рукин К.Ю., Петрова И.В. Роль генетических факторов в механизмах развития ремоделирования коронарных артерий после имплантирования стентов // Бюллетень сибирской медицины. 2015. №1. С. 102-109. URL: https://cyberleninka.ru/article/n/rol-geneticheskih-faktorov-v-mehanizmah-razvitiya-remodelirovaniya-koronarnyh-arteriy-posle-implantirovaniya-stentov (дата обращения: 03.02.2020).
5. Исхаков М.М., Тагирова Д.Р., Газизов Н.В. и др. Феномен «No-reflow»: клинические аспекты неудачи реперфузии // Казанский медицинский журнал. 2015. Том 96, №3. С. 391-396. URL: https://cyberleninka.ru/article/n/fenomen-no-reflow-klinicheskie-aspekty-neudachi-reperfuzii (дата обращения: 02.02.2020).
6. Козлов С.Г., Габбасов З.А., Бязрова С.В. Избыточное образование конечных продуктов гликирования как возможная причина повышенного риска возникновения рестеноза после стентирования коронарных артерий у больных сахарным диабетом // Атеросклероз и дислипидемии. 2015. №3. С. 5-13. URL: https://cyberleninka.ru/article/n/izbytochnoe-obrazovanie-konechnyh-produktov-glikirovaniya-kak-vozmozhnaya-prichina-povyshennogo-riska-vozniknoveniya-restenoza-posle (дата обращения: 27.05.2020).
7. Майлян Д.Э., Афанасьев Ю.И., Гагарина Д.О., Майлян Э.А. Современное состояние проблемы in-stent рестенозов // Научные ведомости БелГУ. Серия: Медицина. Фармация. 2015. Т. 30, №10 (207). С. 12-15. URL: https://cyberleninka.ru/article/n/sovremennoe-sostoyanie-problemy-in-stent-restenozov (дата обращения: 03.02.2020).
8. Плечев В.В., Рисберг Р.Ю., Бузаев И.В., Нигматуллин М.Р. Прогнозирование рестеноза в коронарном стенте при остром коронарном синдроме // Медицинский вестник Башкортостана. 2018. Том 12, №4. С. 14-17. URL: https://cyberleninka.ru/article/n/prognozirovanie-restenoza-v-koronarnom-stente-pri-ostrom-koronarnom-sindrome (дата обращения: 04.02.2020).
9. Проскуряков А.И., Мироненко С.П., Осиев А.Г. Клинико-иммунологические аспекты формирования рестеноза после коронарного стентирования при ИБС // Journal of Siberian Medical Sciences. 2013. №3. С. 8-16. URL: https://cyberleninka.ru/article/n/kliniko-immunologicheskie-aspekty-formirovaniya-restenoza-posle-koronarnogo-stentirovaniya-pri-ibs (дата обращения: 05.02.2020).
10. Самко А.Н., Меркулов Е.В., Власов В.М., Филатов Д.Н. Рестеноз: причины и механизмы развития при различных видах эндоваскулярного лечения // Атеросклероз и дислипидемии. 2014. №1. С. 5-8. URL: https://cyberleninka.ru/article/n/restenoz-prichiny-i-mehanizmy-razvitiya-pri-razlichnyh-vidah-endovaskulyarnogo-lecheniya (дата обращения: 03.02.2020).
11. Ang L. Behnamfar O., Palakodeti S., et. al. Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention // Journal of the American Heart Association. 2015. Volume 6, №11. P. e006580-1-9. URL: https://doi.org/10.1161/JAHA.117.006580 (дата обращения: 03.02.2020).
12. Byrne R.A., Joner M.l, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014 // European Heart Journal. 2015. Volume 36, №47. P. 3320-3331. URL: https://doi.org/10.1093/eurheartj/ehv511 (дата обращения: 28.05.2020).
13. Cai A., Li L. Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement // Journal of Disease Markers. 2013. Vоlume 35, №6. P. 857-862. URL: https://doi.org/10.1155/2013/472845 (дата обращения: 07.02.2020).
14. Çakmak H.A., Demir M. MicroRNA and Cardiovascular Diseases // Balkan medical journal. 2020. Volume 37, №2. P. 60-71. URL: https://doi.org/10.4274/balkanmedj.galenos.2020.2020.1.94 (дата обращения: 03.02.2020).
15. Canfield J., Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions // Journal of personalized medicine. 2018. Volume 8, №4. URL: https://doi.org/10.3390/jpm8040033 (дата обращения: 27.05.2020).
16. Chang M., Park D.W. Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug Eluting Stents: Shorter or Longer? // Journal of Cardiology and Therapy. 2014, №3:1-12. URL: https://doi.org/10.1007/s40119-014-0030-y (дата обращения: 10.02.2020).
17. Chen Y.L., Fan J., Chen G. et al. Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis // Medicine. 2019. Volume 98, №15. e15217. URL: https://doi.org/10.1097/MD.0000000000015217 (дата обращения: 17.06.2020).
18. Cheng G., Chang F.J., Wang Y. et al. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up // Medical science monitor: international medical journal of experimental and clinical research. 2019. Volume 25. P. 240–247. URL: https://doi.org/10.12659/MSM.908692 (дата обращения: 17.06.2020).
19. Cheng L.Y., Wang Y.C., Chen M.H., Tung F.I., Chiu K.M., Liu T.Y. An Engineered Gene Nanovehicle Developed for Smart Gene Therapy to Selectively Inhibit Smooth Muscle Cells: An In Vitro Study // International journal of molecular sciences. 2020. Vоlume 21, №4. P. 1530-1-19. URL: https://doi.org/10.3390/ijms21041530 (дата обращения: 04.02.2020).
20. Cho K.I., Ann S.H., Singh G.B. et al. Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophilto-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent // PLoS One. 2015. Vоlume 10, №7. P. 558-564. URL: https://doi.org/10.1371/journal.pone.0133934 (дата обращения: 10.02.2020).
21. Christ G., Siller-Matula J.M., Francesconi M. et al. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry // BMJ Open. 2014. Vоlume 4, №10. P. 198-202. URL: https://doi.org/10.1136/bmjopen-2014-005781 (дата обращения: 10.02.2020).
22. Cornelissen A., Vogt F.J. The effects of stenting on coronary endothelium fr om a molecular biological view: Time for improvement? // Journal of cellular and molecular medicine. 2019. Volume 23, №1. P. 39-46. https://doi.org/10.1111/jcmm.13936 (дата обращения: 28.05.2020).
23. Farsky P.S., Hirata M.H., Arnoni R.T. et. al. Persistent Inflammatory Activity in Blood Cells and Artery Tissue from Patients with Previous Bare Metal Stent // Arquivos brasileiros de cardiologia. 2018. Volume 111, №2. P. 134-141. URL: https://doi.org/10.5935/abc.20180119 (дата обращения: 27.05.2020).
24. Gan J., Li P. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway // Experimental and therapeutic medicine. 2013. Vоlume 6, №4. P. 899-903. URL: https://doi.org/10.3892/etm.2013.1265 (дата обращения: 07.02.2020).
25. Gilard M., Barragan P., Noryani Arif A.L., Noor Hussam A., Majwal T. et al. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: The Randomized, Multicenter ITALIC Trial // Journal of the American College of Cardiology. 2015. Volume 65, №8. P. 787-790. URL: https://doi.org/10.1016/j.jacc.2014.11.008 (дата обращения: 10.02.2020).
26. Habara M., Terashima M., Nasu K. et al. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study // European Heart Journal - Cardiovascular Imaging. 2013. Volume 14, №3. P. 276-284. URL: https://doi.org/10.1093/ehjci/jes183 (дата обращения: 04.02.2020).
27. He M., Gong Y., Shi J. et al. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis // PLoS One. 2014. Vоlume 9, №11. С. e112043. URL: https://doi.org/10.1371/journal.pone.0112043 (дата обращения: 07.02.2020).
28. Hong S.J., Choi S.Ch., Cho J.Y. et al. Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients – Optical Coherence Tomography Analysis // Circulation Journal. 2015. Volume 89, №4. P. 880-888. URL: https://doi.org/10.1253/circj.CJ-14-0964 (дата обращения: 28.05.2020).
29. Junkar I., Kulkarni M., Benčina M. et al. Titanium Dioxide Nanotube Arrays for Cardiovascular Stent Applications // ACS omega. 2020. Volume 5, №13. P. 7280–7289. URL: https://doi.org/10.1021/acsomega.9b04118 (дата обращения: 17.06.2020).
30. Kavitha S., Sridhar M.G., Satheesh S. Periprocedural plasma fibrinogen levels and coronary stent outcome // Indian heart journal. 2015. Vоlume 67, №5. P. 440-443. URL: https://doi.org/10.1016/j.ihj.2015.06.006 (дата обращения: 05.02.2020).
31. Kedhi E., Genereux P., Palmerini T. et al. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials // Journal of the American College of Cardiology. 2014. Volume 63, №20. P. 2111-2118. URL: https://doi.org/10.1016/j.jacc.2014.01.064 (дата обращения: 28.05.2020).
32. Lee S.Y., Hong M.K., Jang Y. Formation and Transformation of Neointima after Drug-eluting Stent Implantation: Insights from Optical Coherence Tomographic Studies // Korean circulation journal. 2017. Volume 47, №6. P. 823–832. URL: https://doi.org/10.4070/kcj.2017.0157 (дата обращения: 28.05.2020).
33. Lee S.Y., Shin D.H., Kim J.S. et. al. Optical coherence tomographic observation of morphological features of neointimal tissue after drug-eluting stent implantation // Yonsei medical journal. 2014. Volume 55, №4. P. 944–952. URL: https://doi.org/10.3349/ymj.2014.55.4.944 (дата обращения: 28.05.2020).
34. Lim K.S., Jeong M.H. Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis // Korean Circulation Journal. 2013. Vоlume 43, №11. P. 744-751. URL: https://doi.org/10.4070/kcj.2013.43.11.744 (дата обращения: 10.02.2020).
35. Liu J., Li M., Lu H. et al. Effects of Probucol on Restenosis after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis // PLoS ONE. 2015. Volume 10, №4. e0124021. URL: https://doi.org/10.1371/journal.pone.0124021 (дата обращения: 28.05.2020).
36. Lovren F., Pan Y., Quan A. et al. MicroRNA-145 targeted therapy reduces atherosclerosis // Circulation. 2012. Vоlume 126, №11. P. S81-S90. URL: https://doi.org/10.1161/CIRCULATIONAHA.111.084186 (дата обращения: 07.02.2020).
37. Mayyas F.A., Al-Jarrah M.I. Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease // Experimental and therapeutic medicine. 2014. Volume 8, №6. P. 1951-1957. URL: https://doi.org/10.3892/etm.2014.2034 (дата обращения: 05.02.2020).
38. Montalescot G., Brieger D., Dalby A.J., Park S-J., Mehran R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence // Journal of the American College of Cardiology. 2015. Volume 66, №7. P. 832-847. URL: https://doi.org/10.1016/j.jacc.2015.05.053 (дата обращения: 10.02.2020).
39. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization // European heart journal. 2019. Volume 40, №2. P. 87-165. URL: https://doi.org/10.1093/eurheartj/ehy394 (дата обращения: 28.05.2020).
40. O’Sullivan J.F., Neylon A., McGorrian C. et al. MicroRNA expression in coronary artery disease // Microrna. 2014. Volume 2, №3. P. 205-211. URL: https://doi.org/10.2174/22115366113026660018 (дата обращения: 07.02.2020).
41. Omeh D.J., Shlofmitz E. Restenosis // StatPearls Publishing. FL. 2020. 20 p. URL: https://www.ncbi.nlm.nih.gov/books/NBK545139 (дата обращения: 15.02.2020).
42. Paramasivam G., Devasia T., Jayaram A. et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes // Anatolian journal of cardiology. 2020. Volume 23, №1. P. 28–34. URL: https://doi.org/10.14744/AnatolJCardiol.2019.72916 (дата обращения: 17.06.2020).
43. Pendyala L.K., Loh J.P., Kitabata H. et al. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era // Journal of interventional cardiology. 2014. Volume 27, №4. P. 391–398. URL: https://doi.org/10.1111/joic.12136 (дата обращения: 28.05.2020).
44. Peng N., Liu W., Li Z. et al. Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials // Cardiovascular therapeutics. 2020. Volume 2020. URL: https://doi.org/10.1155/2020/1042329 (дата обращения: 17.06.2020).
45. Pleva L., Kukla P., Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review // Journal of geriatric cardiology. 2018. Volume 15, №2. P. 173–184. URL: https://doi.org/10.11909/j.issn.1671-5411.2018.02.007 (дата обращения: 28.05.2020).
46. Ren J, Zhang J, Xu N. et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease // PLoS One. 2013. Volume 8, №12. P. e80738-1-13. URL: https://doi.org/10.1371/journal.pone.0080738 (дата обращения: 05.02.2020).
47. Schulte C., Karakas M., Zeller T. MicroRNAs in vascular disease – clinical application // Clinical Chemistry and Laboratory Medicine. 2017. Volume 55, №5. P. 687-704. URL: https://www.degruyter.com/view/journals/cclm/55/5/article-p687.xml (дата обращения: 07.02.2020).
48. Song J.B., Shen J., Fan J. et al. Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis // Medical science monitor: international medical journal of experimental and clinical research. 2020. Vоlume 112. P. e922556-1-17. URL: https://doi.org/10.12659/MSM.922556 (дата обращения: 10.04.2020).
49. Sun J., Yu H., Liu H. et. al. Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents // Journal of clinical laboratory analysis. 2020. Volume 34, №3. URL: https://doi.org/10.1002/jcla.23108 (дата обращения: 27.05.2020).
50. Tahir H., Bona-Casas C., Hoekstra A.G. Modelling the effect of a functional endothelium on the development of in-stent restenosis // PLoS One. 2013. Volume 8, №6. e66138. URL: https://doi.org/10.1371/journal.pone.0066138 (дата обращения: 02.02.2020).
51. Tang L., Cui Q.W., Liu D.P., Fu Y.Y. The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention // Medicine (Baltimore). 2019. Volume 98, №50. e18312. URL: https://doi.org/10.1097/MD.0000000000018312 (дата обращения: 09.02.2020).
52. Turak O., Ozcan F., Isleyen A. et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis // The American Journal of Cardiology. 2012. Volume 110, №10. P. 1405-1410. URL: https://doi.org/10.1016/j.amjcard.2012.07.003 (дата обращения: 03.02.2020).
53. Verschuren Jeffrey J. W., Trompet S. Postmus I. Systematic Testing of Literature Reported Genetic Variation Associated with Coronary Restenosis: Results of the GENDER Study // PLoS One. 2012. Volume 7, №8. e42401. URL: https://doi.org/10.1371/journal.pone.0042401 (дата обращения: 07.02.2020).
54. Wang B.J., Liu J., Geng J., Zhang Q., Hu T.T., Xu B. Association between three interleukin-10 gene polymorphisms and coronary artery disease risk: a meta-analysis // International journal of clinical and experimental medicine. 2015. Volume 8, №10. P. 17842-17855. PMID: 26770379; PMCID: PMC4694279.
55. Wang S., Dai Y., Chen L., Dong Z. et al. Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies // PLoS One. 2013. Volume 8. e75285. URL: https://doi.org/10.1371/journal.pone.0075285 (дата обращения: 05.02.2020).
56. World Health Organization. About cardiovascular diseases (сайт). 2020. URL: https://www.who.int/cardiovascular_diseases/about_cvd/en/ (дата обращения: 01.02.2020).
57. Yalcin A.A., Topuz M. Role of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy // Postepy Kardiol Interwencyjnej. 2014. Volume 10, №4. P. 242-249. URL: https://doi.org/10.5114/pwki.2014.46765 (дата обращения: 09.02.2020).
58. Yu X., He J., Luo Y. et al. Influence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting // International heart journal. 2015. Volume 56, №1. P. 43–48. URL: https://doi.org/10.1536/ihj.14-193 (дата обращения: 28.05.2020).
59. Yuepeng J., Zhao X., Zhao Y., Li L. Gene polymorphism associated with TNF-α (G308A) IL-6 (C174G) and susceptibility to coronary atherosclerotic heart disease: A meta-analysis // Medicine (Baltimore). 2019. Vоlume 98, №23. P. e13813-1-9. URL: https://doi.org/10.1097/MD.0000000000013813 (дата обращения: 07.02.2020).
60. Zhang M.M., Zheng Y.Y., Gao Y. et al. Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis // Oncotarget. 2016. Vоlume 7, №50. P. 83437-83450. URL: https://doi.org/10.18632/oncotarget.13118 (дата обращения: 07.02.2020).
61. Zhao L., Zhu W., Zhang X., He, D. et al. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis // BMC cardiovascular disorders. 2017. Volume 17, №1. URL: https://doi.org/10.1186/s12872-016-0445-6 (дата обращения: 28.05.2020).
62. Zheng D., Zeng F. Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement // Lipids in Health and Disease. 2014. Volume 13. С. 41. URL: https://doi.org/10.1186/1476-511X-13-41 (дата обращения: 07.02.2020).
63. Zholdybayeva, E.V., Talzhanov, Y.A., Aitkulova, A.M. et. al. Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population // Human Genomics. 2016. Vоlume 10. №1. С. 15. URL: https://doi.org/10.1186/s40246-016-0077-z (дата обращения: 07.02.2020).
64. Zhou S., Mu G., Wei Sh. et. al. Associations Between Polymorphisms of Endothelial Nitric Oxide Synthase, Matrix Metalloproteinase 3, Angiotensinogen, and Angiotensin II Type 1 Receptor and Risk of Restenosis After Percutaneous Coronary Intervention: A Meta-analysis // Clinical Therapeutics. 2020. Volume 42, №3. P. 458-474. URL: https://doi.org/10.1016/J.CLINTHERA.2020.01.018 (дата обращения: 10.04.2020).
65. Zhu M., Yang M., Lin J., Zhu H., Lu Y., Wang B., Xue Y., Fang C., Tang L., Xu B., Jiang J., Chen X. Association of seven renin angiotensin system gene polymorphisms with restenosis in patients following coronary stenting // Journal of the renin-angiotensin-aldosterone system. 2017. Volume 18, №1. URL: https://doi.org/10.1177/1470320316688774 (дата обращения: 07.02.2020).
66. Zhu X., Chen Y., Xiang L. et al. The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis // Medicine (Baltimore). 2018. Volume 97, №27. e10679. URL: https://doi.org/10.1097/MD.0000000000010679 (дата обращения: 28.05.2020).
Reference:
1. Alimov D.A., Zhalalov B.Z., Ganiev U.Sh. Restenoz stenta s tochki zreniya endotelial'noi disfunktsii [Stent restenosis in terms of endothelial dysfunction]. Vestnik ekstrennoi meditsiny [Bulletin of emergency medicine]. 2017. №3. P. 109-112. URL: https://cyberleninka.ru/article/n/restenoz-stenta-s-tochki-zreniya-endotelialnoy-disfunktsii (accessed: 28.05.2020). [in Russian]
2. Berezovskaya G.A., Ganyukov V.I., Karpenko M.A. Restenosis and thrombosis inside the stent: pathogenetic mechanisms of development and prognostic markers [Restenoz i tromboz vnutri stenta: patogeneticheskie mekhanizmy razvitiya i prognosticheskie markery]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2012. №6. P. 91-95. URL: https://doi.org/10.15829/1560-4071-2012-6-91-95 (accessed: 05.02.2020). ). [in Russian]
3. Veselovskaya N.G., Chumakova G.A., Suvorova A.A., Gritsenko O.V., Subbotin E.A. Gendernye razlichiya faktorov riska restenoza koronarnykh arteriy posle ikh stentirovaniya u patsientov s ozhireniem [Gender differences in risk factors for coronary artery restenosis after stenting in obese patients]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2012. №5. P. 64-69. URL: https://www.science-education.ru/ru/article/view?id=7218 (accessed: 03.02.2020). [in Russian]
4. Vintizenko S.I., Ogorodova L.M., Rukin K.Yu., Petrova I.V. Rol' geneticheskikh faktorov v mekhanizmakh razvitiya remodelirovaniya koronarnykh arterii posle implantirovaniya stentov [The role of genetic factors in the mechanisms of development of coronary artery remodeling after stent implantation]. Byulleten' sibirskoi meditsiny. [Bulletin of Siberian medicine]. 2015. №1. P. 102-109. URL: https://cyberleninka.ru/article/n/rol-geneticheskih-faktorov-v-mehanizmah-razvitiya-remodelirovaniya-koronarnyh-arteriy-posle-implantirovaniya-stentov (accessed: 03.02.2020). [in Russian]
5. Iskhakov M.M., Tagirova D.R., Gazizov N.V. et al. Fenomen «No-reflow»: klinicheskie aspekty neudachi reperfuzii [“No-reflow” phenomenon: clinical aspects of reperfusion failure]. Kazanskii meditsinskii zhurnal [Kazan Medical Journal]. 2015. Volume 96, №3. P. 391-396. URL: https://cyberleninka.ru/article/n/fenomen-no-reflow-klinicheskie-aspekty-neudachi-reperfuzii (accessed: 02.02.2020). [in Russian]
6. Kozlov S.G., Gabbasov Z.A., Byazrova S.V. Izbytochnoe obrazovanie konechnykh produktov glikirovaniya kak vozmozhnaya prichina povyshennogo riska vozniknoveniya restenoza posle stentirovaniya koronarnykh arterii u bol'nykh sakharnym diabetom [Excessive formation of end products of glycation as a possible cause of an increased risk of restenosis after stenting of coronary arteries in patients with diabetes]. Ateroskleroz i dislipidemii [Atherosclerosis and dyslipidemias]. 2015. №3. P. 5-13. URL: https://cyberleninka.ru/article/n/izbytochnoe-obrazovanie-konechnyh-produktov-glikirovaniya-kak-vozmozhnaya-prichina-povyshennogo-riska-vozniknoveniya-restenoza-posle (accessed: 27.05.2020). [in Russian]
7. Maylyan D.E., Afanasyev Yu.I., Gagarina D.O., Maylyan E.A. Sovremennoe sostoyanie problemy in-stent restenozov [The current state of the problem of in-stent restenosis]. Nauchnye vedomosti BelGU. Seriya: Meditsina. Farmatsiya. [Scientific statements of BelSU]. Series: Medicine. Pharmacy. 2015. Volume 30, №10(207). P. 12-15. URL: https://cyberleninka.ru/article/n/sovremennoe-sostoyanie-problemy-in-stent-restenozov (accessed: 03.02.2020). [in Russian]
8. Plechev V.V., Risberg R.Yu., Buzaev I.V., Nigmatullin M.R. Prognozirovanie restenoza v koronarnom stente pri ostrom koronarnom sindrome [Prediction of restenosis in the coronary stent in acute coronary syndrome]. Meditsinskii vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2018. Volume 12, №4. P. 14-17. URL: https://cyberleninka.ru/article/n/prognozirovanie-restenoza-v-koronarnom-stente-pri-ostrom-koronarnom-sindrome (accessed: 04.02.2020). [in Russian]
9. Proskuryakov A.I., Mironenko S.P., Osiev A.G. Kliniko-immunologicheskie aspekty formirovaniya restenoza posle koronarnogo stentirovaniya pri IBS [Clinical and immunological aspects of the formation of restenosis after coronary stenting in coronary heart disease]. Journal of Siberian Medical Sciences. 2013. №3. P. 8-16. URL: https://cyberleninka.ru/article/n/kliniko-immunologicheskie-aspekty-formirovaniya-restenoza-posle-koronarnogo-stentirovaniya-pri-ibs (accessed: 05.02.2020). [in Russian]
10. Samko A.N., Merkulov E.V., Vlasov V.M., Filatov D.N. Restenoz: prichiny i mekhanizmy razvitiya pri razlichnykh vidakh endovaskulyarnogo lecheniya // [Restenosis: causes and developmental mechanisms in various types of endovascular treatment]. Ateroskleroz i dislipidemii [Atherosclerosis and dyslipidemia]. 2014. №1. P. 5-8. URL: https://cyberleninka.ru/article/n/restenoz-prichiny-i-mehanizmy-razvitiya-pri-razlichnyh-vidah-endovaskulyarnogo-lecheniya (accessed: 03.02.2020). [in Russian]
11. Ang L. Behnamfar O., Palakodeti S., et. al. Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. Journal of the American Heart Association. 2015. Volume 6, №11. P. e006580-1-9. URL: https://doi.org/10.1161/JAHA.117.006580 (accessed: 03.02.2020).
12. Byrne R.A., Joner M.l, Kastrati A. Stent thrombosis and restenosis: what have we learned and wh ere are we going? The Andreas Grüntzig Lecture ESC 2014. European Heart Journal. 2015. Volume 36, №47. P. 3320-3331. URL: https://doi.org/10.1093/eurheartj/ehv511 (accessed: 28.05.2020).
13. Cai A., Li L. Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement. Journal of Disease Markers. 2013. Vоlume 35, №6. P. 857-862. URL: https://doi.org/10.1155/2013/472845 (accessed: 07.02.2020).
14. Çakmak H.A., Demir M. MicroRNA and Cardiovascular Diseases. Balkan medical journal. 2020. Volume 37, №2. P. 60-71. URL: https://doi.org/10.4274/balkanmedj.galenos.2020.2020.1.94 (accessed: 03.02.2020).
15. Canfield J., Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions. Journal of personalized medicine. 2018. Volume 8, №4. URL: https://doi.org/10.3390/jpm8040033 (accessed: 27.05.2020).
16. Chang M., Park D.W. Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug Eluting Stents: Shorter or Longer? Journal of Cardiology and Therapy. 2014, №3:1-12. URL: https://doi.org/10.1007/s40119-014-0030-y (accessed: 10.02.2020).
17. Chen Y.L., Fan J., Chen G. et al. Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis. Medicine. 2019. Volume 98, №15. e15217. URL: https://doi.org/10.1097/MD.0000000000015217 (accessed: 17.06.2020).
18. Cheng G., Chang F.J., Wang Y. et al. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up. Medical science monitor: international medical journal of experimental and clinical research. 2019. Volume 25. P. 240–247. URL: https://doi.org/10.12659/MSM.908692 (accessed: 17.06.2020).
19. Cheng L.Y., Wang Y.C., Chen M.H., Tung F.I., Chiu K.M., Liu T.Y. An Engineered Gene Nanovehicle Developed for Smart Gene Therapy to Selectively Inhibit Smooth Muscle Cells: An In Vitro Study. International journal of molecular sciences. 2020. Vоlume 21, №4. P. 1530-1-19. URL: https://doi.org/10.3390/ijms21041530 (accessed: 04.02.2020).
20. Cho K.I., Ann S.H., Singh G.B. et al. Combined Usefulness of the Platelet-to-Lymphocyte Ratio and the Neutrophilto-Lymphocyte Ratio in Predicting the Long-Term Adverse Events in Patients Who Have Undergone Percutaneous Coronary Intervention with a Drug-Eluting Stent. PLoS One. 2015. Vоlume 10, №7. P. 558-564. URL: https://doi.org/10.1371/journal.pone.0133934 (accessed: 10.02.2020).
21. Christ G., Siller-Matula J.M., Francesconi M. et al. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open. 2014. Vоlume 4, №10. P. 198-202. URL: https://doi.org/10.1136/bmjopen-2014-005781 (accessed: 10.02.2020).
22. Cornelissen A., Vogt F.J. The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement? Journal of cellular and molecular medicine. 2019. Volume 23, №1. P. 39-46. https://doi.org/10.1111/jcmm.13936 (accessed: 28.05.2020).
23. Farsky P.S., Hirata M.H., Arnoni R.T. et. al. Persistent Inflammatory Activity in Blood Cells and Artery Tissue from Patients with Previous Bare Metal Stent. Arquivos brasileiros de cardiologia. 2018. Volume 111, №2. P. 134-141. URL: https://doi.org/10.5935/abc.20180119 (accessed: 27.05.2020).
24. Gan J., Li P. Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Experimental and therapeutic medicine. 2013. Vоlume 6, №4. P. 899-903. URL: https://doi.org/10.3892/etm.2013.1265 (accessed: 07.02.2020).
25. Gilard M., Barragan P., Noryani Arif A.L., Noor Hussam A., Majwal T. et al. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: The Randomized, Multicenter ITALIC Trial. Journal of the American College of Cardiology. 2015. Volume 65, №8. P. 787-790. URL: https://doi.org/10.1016/j.jacc.2014.11.008 (accessed: 10.02.2020).
26. Habara M., Terashima M., Nasu K. et al. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study. European Heart Journal - Cardiovascular Imaging. 2013. Volume 14, №3. P. 276-284. URL: https://doi.org/10.1093/ehjci/jes183 (accessed: 04.02.2020).
27. He M., Gong Y., Shi J. et al. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis. PLoS One. 2014. Vоlume 9, №11. С. e112043. URL: https://doi.org/10.1371/journal.pone.0112043 (accessed: 07.02.2020).
28. Hong S.J., Choi S.Ch., Cho J.Y. et al. Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients – Optical Coherence Tomography Analysis. Circulation Journal. 2015. Volume 89, №4. P. 880-888. URL: https://doi.org/10.1253/circj.CJ-14-0964 (accessed: 28.05.2020).
29. Junkar I., Kulkarni M., Benčina M. et al. Titanium Dioxide Nanotube Arrays for Cardiovascular Stent Applications. ACS omega. 2020. Volume 5, №13. P. 7280–7289. URL: https://doi.org/10.1021/acsomega.9b04118 (accessed: 17.06.2020).
30. Kavitha S., Sridhar M.G., Satheesh S. Periprocedural plasma fibrinogen levels and coronary stent outcome. Indian heart journal. 2015. Vоlume 67, №5. P. 440-443. URL: https://doi.org/10.1016/j.ihj.2015.06.006 (accessed:: 05.02.2020).
31. Kedhi E., Genereux P., Palmerini T. et al. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. Journal of the American College of Cardiology. 2014. Volume 63, №20. P. 2111-2118. URL: https://doi.org/10.1016/j.jacc.2014.01.064 (accessed: 28.05.2020).
32. Lee S.Y., Hong M.K., Jang Y. Formation and Transformation of Neointima after Drug-eluting Stent Implantation: Insights from Optical Coherence Tomographic Studies. Korean circulation journal. 2017. Volume 47, №6. P. 823–832. URL: https://doi.org/10.4070/kcj.2017.0157 (accessed: 28.05.2020).
33. Lee S.Y., Shin D.H., Kim J.S. et. al. Optical coherence tomographic observation of morphological features of neointimal tissue after drug-eluting stent implantation. Yonsei medical journal. 2014. Volume 55, №4. P. 944–952. URL: https://doi.org/10.3349/ymj.2014.55.4.944 (accessed: 28.05.2020).
34. Lim K.S., Jeong M.H. Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis. Korean Circulation Journal. 2013. Vоlume 43, №11. P. 744-751. URL: https://doi.org/10.4070/kcj.2013.43.11.744 (accessed: 10.02.2020).
35. Liu J., Li M., Lu H. et al. Effects of Probucol on Restenosis after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. PLoS ONE. 2015. Volume 10, №4. e0124021. URL: https://doi.org/10.1371/journal.pone.0124021 (accessed: 28.05.2020).
36. Lovren F., Pan Y., Quan A. et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation. 2012. Vоlume 126, №11. P. S81-S90. URL: https://doi.org/10.1161/CIRCULATIONAHA.111.084186 (accessed: 07.02.2020).
37. Mayyas F.A., Al-Jarrah M.I. Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease. Experimental and therapeutic medicine. 2014. Volume 8, №6. P. 1951-1957. URL: https://doi.org/10.3892/etm.2014.2034 (accessed: 05.02.2020).
38. Montalescot G., Brieger D., Dalby A.J., Park S-J., Mehran R. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. Journal of the American College of Cardiology. 2015. Volume 66, №7. P. 832-847. URL: https://doi.org/10.1016/j.jacc.2015.05.053 (accessed: 10.02.2020).
39. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European heart journal. 2019. Volume 40, №2. P. 87-165. URL: https://doi.org/10.1093/eurheartj/ehy394 (accessed: 28.05.2020).
40. O’Sullivan J.F., Neylon A., McGorrian C. et al. MicroRNA expression in coronary artery disease. Microrna. 2014. Volume 2, №3. P. 205-211. URL: https://doi.org/10.2174/22115366113026660018 (accessed: 07.02.2020).
41. Omeh D.J., Shlofmitz E. Restenosis. StatPearls Publishing. FL. 2020. 20 p. URL: https://www.ncbi.nlm.nih.gov/books/NBK545139 (accessed: 15.02.2020).
42. Paramasivam G., Devasia T., Jayaram A. et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. Anatolian journal of cardiology. 2020. Volume 23, №1. P. 28–34. URL: https://doi.org/10.14744/AnatolJCardiol.2019.72916 (accessed: 17.06.2020).
43. Pendyala L.K., Loh J.P., Kitabata H. et al. The impact of diabetes mellitus on long-term clinical outcomes after percutaneous coronary saphenous vein graft interventions in the drug-eluting stent era. Journal of interventional cardiology. 2014. Volume 27, №4. P. 391–398. URL: https://doi.org/10.1111/joic.12136 (accessed: 28.05.2020).
44. Peng N., Liu W., Li Z. et al. Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials. Cardiovascular therapeutics. 2020. Volume 2020. URL: https://doi.org/10.1155/2020/1042329 (accessed: 17.06.2020).
45. Pleva L., Kukla P., Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. Journal of geriatric cardiology. 2018. Volume 15, №2. P. 173–184. URL: https://doi.org/10.11909/j.issn.1671-5411.2018.02.007 (accessed: 28.05.2020).
46. Ren J, Zhang J, Xu N. et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One. 2013. Volume 8, №12. P. e80738-1-13. URL: https://doi.org/10.1371/journal.pone.0080738 (accessed: 05.02.2020).
47. Schulte C., Karakas M., Zeller T. MicroRNAs in vascular disease – clinical application. Clinical Chemistry and Laboratory Medicine. 2017. Volume 55, №5. P. 687-704. URL: https://www.degruyter.com/view/journals/cclm/55/5/article-p687.xml (accessed: 07.02.2020).
48. Song J.B., Shen J., Fan J. et al. Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis. Medical science monitor: international medical journal of experimental and clinical research. 2020. Vоlume 112. P. e922556-1-17. URL: https://doi.org/10.12659/MSM.922556 (accessed: 10.04.2020).
49. Sun J., Yu H., Liu H. et. al. Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents. Journal of clinical laboratory analysis. 2020. Volume 34, №3. URL: https://doi.org/10.1002/jcla.23108 (accessed: 27.05.2020).
50. Tahir H., Bona-Casas C., Hoekstra A.G. Modelling the effect of a functional endothelium on the development of in-stent restenosis. PLoS One. 2013. Volume 8, №6. e66138. URL: https://doi.org/10.1371/journal.pone.0066138 (accessed: 02.02.2020).
51. Tang L., Cui Q.W., Liu D.P., Fu Y.Y. The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention. Medicine (Baltimore). 2019. Volume 98, №50. e18312. URL: https://doi.org/10.1097/MD.0000000000018312 (accessed: 09.02.2020).
52. Turak O., Ozcan F., Isleyen A. et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. The American Journal of Cardiology. 2012. Volume 110, №10. P. 1405-1410. URL: https://doi.org/10.1016/j.amjcard.2012.07.003 (accessed: 03.02.2020).
53. Verschuren Jeffrey J. W., Trompet S. Postmus I. Systematic Testing of Literature Reported Genetic Variation Associated with Coronary Restenosis: Results of the GENDER Study. PLoS One. 2012. Volume 7, №8. e42401. URL: https://doi.org/10.1371/journal.pone.0042401 (accessed: 07.02.2020).
54. Wang B.J., Liu J., Geng J., Zhang Q., Hu T.T., Xu B. Association between three interleukin-10 gene polymorphisms and coronary artery disease risk: a meta-analysis. International journal of clinical and experimental medicine. 2015. Volume 8, №10. P. 17842-17855. PMID: 26770379; PMCID: PMC4694279.
55. Wang S., Dai Y., Chen L., Dong Z. et al. Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies. PLoS One. 2013. Volume 8. e75285. URL: https://doi.org/10.1371/journal.pone.0075285 (accessed: 05.02.2020).
56. World Health Organization. About cardiovascular diseases (сайт). 2020. URL: https://www.who.int/cardiovascular_diseases/about_cvd/en/ (accessed: 01.02.2020).
57. Yalcin A.A., Topuz M. Role of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy. Postepy Kardiol Interwencyjnej. 2014. Volume 10, №4. P. 242-249. URL: https://doi.org/10.5114/pwki.2014.46765 (accessed: 09.02.2020).
58. Yu X., He J., Luo Y. et al. Influence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting. International heart journal. 2015. Volume 56, №1. P. 43–48. URL: https://doi.org/10.1536/ihj.14-193 (accessed: 28.05.2020).
59. Yuepeng J., Zhao X., Zhao Y., Li L. Gene polymorphism associated with TNF-α (G308A) IL-6 (C174G) and susceptibility to coronary atherosclerotic heart disease: A meta-analysis. Medicine (Baltimore). 2019. Vоlume 98, №23. P. e13813-1-9. URL: https://doi.org/10.1097/MD.0000000000013813 (accessed: 07.02.2020).
60. Zhang M.M., Zheng Y.Y., Gao Y. et al. Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis. Oncotarget. 2016. Vоlume 7, №50. P. 83437-83450. URL: https://doi.org/10.18632/oncotarget.13118 (accessed: 07.02.2020).
61. Zhao L., Zhu W., Zhang X., He, D. et al. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC cardiovascular disorders. 2017. Volume 17, №1. URL: https://doi.org/10.1186/s12872-016-0445-6 (accessed: 28.05.2020).
62. Zheng D., Zeng F. Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids in Health and Disease. 2014. Volume 13. С. 41. URL: https://doi.org/10.1186/1476-511X-13-41 (accessed: 07.02.2020).
63. Zholdybayeva, E.V., Talzhanov, Y.A., Aitkulova, A.M. et. al. Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population. Human Genomics. 2016. Vоlume 10. №1. С. 15. URL: https://doi.org/10.1186/s40246-016-0077-z (accessed: 07.02.2020).
64. Zhou S., Mu G., Wei Sh. et. al. Associations Between Polymorphisms of Endothelial Nitric Oxide Synthase, Matrix Metalloproteinase 3, Angiotensinogen, and Angiotensin II Type 1 Receptor and Risk of Restenosis After Percutaneous Coronary Intervention: A Meta-analysis. Clinical Therapeutics. 2020. Volume 42, №3. P. 458-474. URL: https://doi.org/10.1016/J.CLINTHERA.2020.01.018 (accessed: 10.04.2020).
65. Zhu M., Yang M., Lin J., Zhu H., Lu Y., Wang B., Xue Y., Fang C., Tang L., Xu B., Jiang J., Chen X. Association of seven renin angiotensin system gene polymorphisms with restenosis in patients following coronary stenting. Journal of the renin-angiotensin-aldosterone system. 2017. Volume 18, №1. URL: https://doi.org/10.1177/1470320316688774 (accessed: 07.02.2020).
66. Zhu X., Chen Y., Xiang L. et al. The long-term prognostic significance of high-sensitive C-reactive protein to in-stent restenosis. Medicine (Baltimore). 2018. Volume 97, №27. e10679. URL: https://doi.org/10.1097/MD.0000000000010679 (accessed: 28.05.2020).
Количество просмотров: 668
Категория статей:
Обзор литературы
Библиографическая ссылка
Землянская Н.С., Дербисалина Г.А., Арипов М.А., Землянский В.В. Современное состояние проблемы рестеноза коронарных артерий после эндоваскулярного стентирования: обзор литературы // Наука и Здравоохранение. 2020. 4 (Т.22). С. 32-48. doi:10.34689/SH.2020.22.4.004Похожие публикации:
ДИАГНОСТИЧЕСКАЯ И ТЕРАПЕВТИЧЕСКАЯ ЛАПАРОСКОПИЯ ПРИ ТРАВМАХ ЖИВОТА. ОБЗОР ЛИТЕРАТУРЫ.
КАЧЕСТВО ЖИЗНИ И МЕТОДЫ ЕГО ОЦЕНКИ ПРИ ПЕРВИЧНОМ БИЛИАРНОМ ХОЛАНГИТЕ
ЛЕКАРСТВЕННО-ИНДУЦИРОВАННЫЕ ПОРАЖЕНИЯ ПЕЧЕНИ И ГЕНДЕРНЫЕ РАЗЛИЧИЯ
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
НОВЫЕ СИНДРОМЫ И ПАТТЕРНЫ ОСТРОЙ ОККЛЮЗИИ КОРОНАРНЫХ АРТЕРИЙ. ОБЗОР ЛИТЕРАТУРЫ.